Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Androxal in Elderly vs Younger Men
NCT02169804Phase 1Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Aug 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enclomiphene in secondary hypogonadism (HH) (2 arms), sponsored by Repros Therapeutics Inc. Primary endpoints: Maximum Plasma Concentration at 4 days, Time to Maximum Plasma Concentration at 4 days and 3 more. Started Aug 2014; status: completed.
02
Drugs
enclomiphene
03
Conditions
secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT02169804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169804.